Table 1. Characteristics of patients between with and without lumbar puncture in non-SCNSV groups

|  |  |  |  |
| --- | --- | --- | --- |
|  | Lumbar puncture (+) | Lumbar puncture (-) | P value |
| N=10 | N=21 |
| Age at onset of GCA, years, median (IQR) | 77 (71-80) | 75 (68-82) | 085 |
| Sex, female (%) | 8 (80%) | 15 (71%) | 1.00 |
| Body weight, kg, median (IQR) | 53 (47-63) | 49 (42-55) | 0.29 |
| Ocular involvement, n (%) | 5 (50%) | 2 (10%) | 0.02\* |
| Blindness, n (%) | 3 (30%) | 1 (5%) | 0.09 |
| Retinal hemorrhage, n (%) | 2 (20%) | 0 (0%) | 0.10 |
| Permanent field defect, n (%) | 0 (0%) | 1 (5%) | 1.00 |
| Polymyalgia rheumatica, n (%) | 3 (30%) | 13 (62%) | 0.14 |
| Hypertension, n (%) | 6 (60%) | 9 (43%) | 0.46 |
| Diabetes mellitus, n (%) | 2 (20%) | 7 (33%) | 0.68 |
| Dyslipidemia, n (%) | 3 (30%) | 6 (29%) | 1.00 |
| Ever or current smoker, n (%) | 2 (20%) | 5 (24%) | 1.00 |
| History of malignancy, n (%) | 1 (10%) | 4 (19%) | 1.00 |
| WBC, /μL, median (IQR) | 7200 (5750-7825) | 7600 (6100-9200) | 0.23 |
| Hemoglobin, g/dL, median (IQR) | 11.3 (9.8-12.1) | 10.1 (9.2-11) | 0.11 |
| Platelet count, /μL, median (IQR) | 35 (31-42) | 34 (27-43) | 0.63 |
| ESR, mm, median (IQR) | 113 (84-128) | 116 (87-123) | 0.63 |
| Lactate dehydrogenase, U/L, median (IQR) | 156 (116-190) | 151 (136-172) | 0.82 |
| Albumin, g/dL, median (IQR) | 3 (2.8-3.2) | 2.9 (2.7-3.4) | 0.79 |
| Blood urea nitrogen, mg/dL, median (IQR) | 12 (9-15) | 12 (11-16) | 0.69 |
| Serum creatinine, mg/dL, median (IQR) | 0.48 (0.44-0.56) | 0.57 (0.52-0.66) | 0.04\* |
| eGFR, mL/min/1.73m2, median (IQR) | 99 (83-115) | 82 (69-92) | 0.72 |
| Ferritin, ng/ml, median (IQR) | 280 (195-416) | 323 (205-474) | 0.65 |
| CRP, mg/dL, median (IQR) | 5 (3-12) | 5 (3-9) | 0.95 |
| IgG, mg/dL, median (IQR) | 1370 (1235-1620) | 1514 (1152-1737) | 0.85 |
| CH50, U/mL, median (IQR) | 65 (57-75) | 62 (47-68) | 0.17 |
| C3, mg/dL, median (IQR) | 142 (135-169) | 125 (106-146) | 0.015\* |
| C4, mg/dl, median (IQR) | 38 (28-44) | 33 (28-43) | 0.60 |
| Positive anti-phospholipid antibodies, n (%) | 5 (50%) | 5 (24%) | 0.23 |
| Age at onset of GCA, ≥50 years, n (%) | 10 (100%) | 21 (100%) | N/A |
| New headache, n (%) | 9 (90%) | 16 (76%) | 0.63 |
| Temporal artery abnormality, n (%) | 8 (80%) | 14 (67%) | 0.68 |
| Elevated ESR, n (%) | 10 (100%) | 20 (95%) | 1.00 |
| Abnormal artery biopsy findings, n (%) | 5 (100%) | 8 (80%) | 0.52 |
| Initial dose of oral GC, mg/body/day, median (IQR) | 40 (38-43) | 40 (38-48) | 0.93 |
| Steroid pulse therapy, n (%) | 2 (20%) | 1 (5%) | 0.24 |
| Immunosuppressant as initial therapy for GCA, n (%) | 1 (10%) | 0 (0%) | 0.32 |
| Anticoagulant, n (%) | 0 (0%) | 3 (14%) | 0.53 |
| Anti-platelet therapy, n (%) | 7 (70%) | 16 (76%) | 1.00 |
| Relapse, n (%) | 0 (0%) | 3 (14%) | 0.53 |
| Death, n (%) | 0 (0%) | 3 (14%) | 0.53 |

GC doses are expressed as prednisolone equivalents. \**p*<0.05, \*\**p*<0.01.

SCNSV, secondary central nervous system vasculitis; GCA, giant cell arteritis; IQR, interquartile range; WBC, white blood cell; ESR, erythrocyte sedimentation rate; eGFR, estimated glomerular filtration rate; CRP, C reactive protein; IgG, immunoglobulin G; CH50, 50% hemolytic complement activity; GC, glucocorticoid; N/A, not applicable.